Fundación CENIT para la Investigación en Neurociencias
Fundación CENIT para la Investigación en Neurociencias
Juncal 2222, C1125 CABA, Argentina
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Guillermo Lerzo
Ernesto Korbenfeld
Mónica Casalnuovo
Oscar Luis Rillo
Claudio Campos
Natalia Baltz Hehn
Graciela Acosta
Violeta Bertolini
Open studies
Lung cancer
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. - Be6A Lung-02 - PfizerSee more
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer - DESTINY-Lung06 - Daiichi SankyoSee more
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVieSee more
Breast Cancer
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - EvoPAR-BR01 - AstraZenecaSee more
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) - TROPION-Breast05 - AstraZenecaSee more
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy - INAVO121 - Hoffmann-La RocheSee more
Endometrial Cancer
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) - Bluestar-Endometrial01 - AstraZenecaSee more
Gastroesophageal cancer
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer - HLX22-GC-301 - Shanghai Henlius BiotechSee more
